441 related articles for article (PubMed ID: 12916059)
1. Non-thiol farnesyltransferase inhibitors: FTase-inhibition and cellular activity of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Mitsch A; Bergemann S; Gust R; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):242-50. PubMed ID: 12916059
[TBL] [Abstract][Full Text] [Related]
2. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Schlitzer M; Böhm M; Sattler I
Bioorg Med Chem; 2002 Mar; 10(3):615-20. PubMed ID: 11814849
[TBL] [Abstract][Full Text] [Related]
3. Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides.
Mitsch A; Wissner P; Silber K; Haebel P; Sattler I; Klebe G; Schlitzer M
Bioorg Med Chem; 2004 Sep; 12(17):4585-600. PubMed ID: 15358286
[TBL] [Abstract][Full Text] [Related]
4. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by 5-cinnamoylaminobenzophenones.
Mitsch A; Wissner P; Böhm M; Silber K; Klebe G; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Sep; 337(9):493-501. PubMed ID: 15362122
[TBL] [Abstract][Full Text] [Related]
5. Non-thiol farnesyltransferase inhibitors: utilization of the near aryl binding site by 5-arylacetylaminobenzophenones.
Mitsch A; Böhm M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2004 Apr; 337(4):213-8. PubMed ID: 15065081
[TBL] [Abstract][Full Text] [Related]
6. Non-thiol farnesyltransferase inhibitors: the concept of benzophenone-based bisubstrate analogue farnesyltransferase inhibitors.
Schlitzer M; Sattler I
Eur J Med Chem; 2000; 35(7-8):721-6. PubMed ID: 10960188
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.
Lombardo LJ; Camuso A; Clark J; Fager K; Gullo-Brown J; Hunt JT; Inigo I; Kan D; Koplowitz B; Lee F; McGlinchey K; Qian L; Ricca C; Rovnyak G; Traeger S; Tokarski J; Williams DK; Wu LI; Zhao Y; Manne V; Bhide RS
Bioorg Med Chem Lett; 2005 Apr; 15(7):1895-9. PubMed ID: 15780629
[TBL] [Abstract][Full Text] [Related]
8. Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity.
Kettler K; Wiesner J; Silber K; Haebel P; Ortmann R; Sattler I; Dahse HM; Jomaa H; Klebe G; Schlitzer M
Eur J Med Chem; 2005 Jan; 40(1):93-101. PubMed ID: 15642414
[TBL] [Abstract][Full Text] [Related]
9. Non-thiol farnesyltransferase inhibitors: N-(4-Acylamino-3-benzoylphenyl)-4-nitrocinnamic acid amides.
Sakowski J; Sattler I; Schlitzer M
Bioorg Med Chem; 2002 Feb; 10(2):233-9. PubMed ID: 11741771
[TBL] [Abstract][Full Text] [Related]
10. Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials.
Kohring K; Wiesner J; Altenkämper M; Sakowski J; Silber K; Hillebrecht A; Haebel P; Dahse HM; Ortmann R; Jomaa H; Klebe G; Schlitzer M
ChemMedChem; 2008 Aug; 3(8):1217-31. PubMed ID: 18470859
[TBL] [Abstract][Full Text] [Related]
11. Structure based design of benzophenone-based non-thiol farnesyltransferase inhibitors.
Schlitzer M
Curr Pharm Des; 2002; 8(19):1713-22. PubMed ID: 12171543
[TBL] [Abstract][Full Text] [Related]
12. C-terminal modifications of histidyl-N-benzylglycinamides to give improved inhibition of Ras farnesyltransferase, cellular activity, and anticancer activity in mice.
McNamara DJ; Dobrusin E; Leonard DM; Shuler KR; Kaltenbronn JS; Quin J; Bur S; Thomas CE; Doherty AM; Scholten JD; Zimmerman KK; Gibbs BS; Gowan RC; Latash MP; Leopold WR; Przybranowski SA; Sebolt-Leopold JS
J Med Chem; 1997 Oct; 40(21):3319-22. PubMed ID: 9341905
[No Abstract] [Full Text] [Related]
13. Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by arylthienylacryloylaminobenzophenones.
Mitsch A; Altenkämper M; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2005 Jan; 338(1):9-17. PubMed ID: 15674808
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, molecular modeling, and structure-activity relationship of benzophenone-based CAAX-peptidomimetic farnesyltransferase inhibitors.
Sakowski J; Böhm M; Sattler I; Dahse HM; Schlitzer M
J Med Chem; 2001 Aug; 44(18):2886-99. PubMed ID: 11520197
[TBL] [Abstract][Full Text] [Related]
15. Non-thiol farnesyltransferase inhibitors: structure-activity relationships of aralkylsubstituted benzophenones.
Mitsch A; Wissner P; Sattler I; Schlitzer M
Arch Pharm (Weinheim); 2001 Feb; 334(2):40-4. PubMed ID: 11268773
[TBL] [Abstract][Full Text] [Related]
16. Non-thiol farnesyltransferase inhibitors: utilization of an aryl binding site by 5-arylacryloylaminobenzophenones.
Mitsch A; Böhm M; Wissner P; Sattler I; Schlitzer M
Bioorg Med Chem; 2002 Aug; 10(8):2657-62. PubMed ID: 12057654
[TBL] [Abstract][Full Text] [Related]
17. Discovery and structure-activity relationships of novel piperidine inhibitors of farnesyltransferase.
Nara S; Tanaka R; Eishima J; Hara M; Takahashi Y; Otaki S; Foglesong RJ; Hughes PF; Turkington S; Kanda Y
J Med Chem; 2003 Jun; 46(12):2467-73. PubMed ID: 12773050
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of homofarnesoyl-substituted CAAX-peptidomimetics as farnesyltransferase inhibitors and antiproliferative agents.
Schlitzer M; Sattler I; Dahse HM
Bioorg Med Chem; 1999 Sep; 7(9):2037-45. PubMed ID: 10530953
[TBL] [Abstract][Full Text] [Related]
19. Novel conformationally extended naphthalene-based inhibitors of farnesyltransferase.
Burns CJ; Guitton JD; Baudoin B; Lelièvre Y; Duchesne M; Parker F; Fromage N; Commerçon A
J Med Chem; 1997 Jun; 40(12):1763-7. PubMed ID: 9191950
[No Abstract] [Full Text] [Related]
20. Structure-activity relationships of novel anti-malarial agents part 8. Effect of different central aryls in biarylacryloylaminobenzophenones on antimalarial activity.
Wiesner J; Mitsch A; Altenkämper M; Ortmann R; Jomaa H; Schlitzer M
Pharmazie; 2003 Dec; 58(12):854-6. PubMed ID: 14703959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]